JP2022549601A5 - - Google Patents

Info

Publication number
JP2022549601A5
JP2022549601A5 JP2022517389A JP2022517389A JP2022549601A5 JP 2022549601 A5 JP2022549601 A5 JP 2022549601A5 JP 2022517389 A JP2022517389 A JP 2022517389A JP 2022517389 A JP2022517389 A JP 2022517389A JP 2022549601 A5 JP2022549601 A5 JP 2022549601A5
Authority
JP
Japan
Prior art keywords
methyl
pyridine
pharmaceutically acceptable
acceptable salt
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549601A (ja
JP7695232B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051249 external-priority patent/WO2021055589A1/en
Publication of JP2022549601A publication Critical patent/JP2022549601A/ja
Publication of JP2022549601A5 publication Critical patent/JP2022549601A5/ja
Priority to JP2025094801A priority Critical patent/JP2025124882A/ja
Application granted granted Critical
Publication of JP7695232B2 publication Critical patent/JP7695232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517389A 2019-09-18 2020-09-17 ヘテロアリール血漿カリクレインインヒビター Active JP7695232B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025094801A JP2025124882A (ja) 2019-09-18 2025-06-06 ヘテロアリール血漿カリクレインインヒビター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902333P 2019-09-18 2019-09-18
US62/902,333 2019-09-18
PCT/US2020/051249 WO2021055589A1 (en) 2019-09-18 2020-09-17 Heteroaryl plasma kallikrein inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025094801A Division JP2025124882A (ja) 2019-09-18 2025-06-06 ヘテロアリール血漿カリクレインインヒビター

Publications (3)

Publication Number Publication Date
JP2022549601A JP2022549601A (ja) 2022-11-28
JP2022549601A5 true JP2022549601A5 (enExample) 2023-09-25
JP7695232B2 JP7695232B2 (ja) 2025-06-18

Family

ID=72670837

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517389A Active JP7695232B2 (ja) 2019-09-18 2020-09-17 ヘテロアリール血漿カリクレインインヒビター
JP2025094801A Pending JP2025124882A (ja) 2019-09-18 2025-06-06 ヘテロアリール血漿カリクレインインヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025094801A Pending JP2025124882A (ja) 2019-09-18 2025-06-06 ヘテロアリール血漿カリクレインインヒビター

Country Status (5)

Country Link
US (2) US11370803B2 (enExample)
EP (1) EP4031245A1 (enExample)
JP (2) JP7695232B2 (enExample)
CN (1) CN114667289B (enExample)
WO (1) WO2021055589A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4494698A3 (en) * 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) * 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPH0832707B2 (ja) 1986-02-05 1996-03-29 富山化学工業株式会社 新規なセフアロスポリン類およびその塩
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
ATE216247T1 (de) 1991-05-20 2002-05-15 Rhone Poulenc Rorer Internat H Aromatische oligomere verbindungen als imitatoren bioaktives makromoleküle
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
JP2000256286A (ja) 1999-03-11 2000-09-19 Kaken Pharmaceut Co Ltd アルキルアミン誘導体
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AU2004255913B2 (en) 2003-07-09 2007-10-11 Takeda Pharmaceutical Company Limited Organosilicon compounds and their use
EP1758579A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
WO2006091898A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2007009236A1 (en) 2005-07-20 2007-01-25 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP1908762A2 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
CN101842098A (zh) 2007-08-10 2010-09-22 基因实验室技术有限公司 用于治疗病毒感染的含氮的二环化学实体
KR100994115B1 (ko) 2008-08-18 2010-11-15 삼성모바일디스플레이주식회사 광효율 개선층을 구비한 유기 발광 소자
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
AU2010239188B2 (en) 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
CA2760778A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
TW201109327A (en) 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
JP2012111731A (ja) 2010-11-26 2012-06-14 Otsuka Pharmaceut Co Ltd 医薬
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
WO2013052526A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
WO2013081094A1 (ja) 2011-11-30 2013-06-06 東レ株式会社 イミダゾ[1,2-a]ピリジン誘導体及びその医薬用途
MX352861B (es) 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
HRP20170411T1 (hr) 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US9624170B2 (en) 2013-12-26 2017-04-18 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors
US10266515B2 (en) 2013-12-30 2019-04-23 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3152206A1 (en) 2014-06-06 2017-04-12 Biogen MA Inc. Atx modulating agents
KR102286305B1 (ko) 2014-07-16 2021-08-09 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
EP3578541B1 (en) 2015-04-17 2025-05-28 Corteva Agriscience LLC Compositions comprising molecules having pesticidal utility, and processes related thereto
WO2017001936A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2017001926A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Therapeutic inhibitory compounds
WO2017098328A2 (en) 2015-12-11 2017-06-15 Lifesci Phamaceuticals, Inc. Therapeutic inhibitory compounds
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
ME03794B (me) 2016-05-31 2021-04-20 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018015818A2 (en) 2016-07-15 2018-01-25 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質の阻害剤
US11111245B2 (en) 2017-02-01 2021-09-07 Aucentra Therapeutics Pty Ltd Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN110678466B (zh) 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
WO2018229543A2 (en) 2017-06-14 2018-12-20 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
EP4494698A3 (en) 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
WO2021004535A1 (en) 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Cinnolines as inhibitors of hpk 1
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
CN114605401B (zh) 2020-04-28 2023-08-22 江南大学 一类含氧五元杂环化合物、合成方法、药物组合物及用途
EP4210694B1 (en) 2020-09-10 2025-10-15 Merck Sharp & Dohme LLC Plasma kallikrein inhibitors
WO2022197755A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Imidazopyridinyl inhibitors of plasma kallikrein
US20240199613A1 (en) 2021-03-17 2024-06-20 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
US20240226106A1 (en) 2021-03-17 2024-07-11 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein
EP4585265A3 (en) 2021-03-17 2025-10-15 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein
US20240382482A1 (en) 2021-03-17 2024-11-21 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors

Similar Documents

Publication Publication Date Title
JP2022548696A5 (enExample)
KR100207360B1 (ko) 이미다조[1,5,-a]퀸옥살린
CN105473573B (zh) 用作激酶抑制剂的咔唑甲酰胺化合物
CN105358546B (zh) 用作激酶抑制剂的经取代的四氢咔唑及咔唑甲酰胺化合物
KR102093608B1 (ko) 이미다조피리딘 화합물
JP2009536620A5 (enExample)
RS60312B1 (sr) Jedinjenja indol karboksamida korisna kao inhibitori kinaze
JP6592512B2 (ja) 三環式アトロプ異性体の化合物
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
JPWO2001060803A1 (ja) 縮合イミダゾリウム誘導体
JP2020524148A (ja) 置換5−シアノインドール化合物及びその使用
GB2265372A (en) Pyrrolo-pyridazinone derivatives and pharmaceutical uses thereof
JP2025131661A (ja) 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態
CN106795152B (zh) 蛋白激酶抑制剂
CN107074856A (zh) CaMKII抑制剂及其用途
JP2002544258A (ja) イオンチャネル調節剤
CA2532437C (en) N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto
JP2019536759A (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
CN121226319A (zh) 烯基取代的哌啶类化合物及其药物组合物、制备方法和用途
TWI708764B (zh) 一種雄性激素受體抑制劑的結晶形式及其製備方法
CN103435562B (zh) 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
JP2011500537A5 (enExample)
JPH07502523A (ja) 抗レトロウイルス作用を有する化合物としての複素環置換ベンジルアミン誘導体
CN106905248A (zh) 川芎嗪并环类化合物、其药物组合物及在药物中的应用
WO2024217521A1 (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物枸橼酸盐的晶型、制备方法及其应用